Hygeia Healthcare : RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND VICE CHAIRMAN

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hygeia Healthcare Holdings Co., Limited ऎΛԭᔼᐕછٰϞࠢʮ̡

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6078)

RESIGNATION OF NON-EXECUTIVE DIRECTOR

AND

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND VICE CHAIRMAN

The Board hereby announces that, with effect from March 30, 2021:

• 1. Mr. Cao Yanling has resigned as a non-executive Director of the Company; and

• 2. Mr. Zhu Yiwen has been appointed as a non-executive Director and vice chairman of the Company.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the "Board") of directors (the "Directors") of Hygeia Healthcare Holdings Co., Limited (the "Company", together with its subsidiaries, the "Group") announces that Mr. Cao Yanling ("Mr. Cao") has tendered his resignation as a non-executive Director with effect from March 30, 2021 in order to devote more time to focus on his other business commitments.

Mr. Cao has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Board would like to take this opportunity to express its gratitude to Mr. Cao for his invaluable contribution and continuous provision of strong support and assistance to the Company during his tenure of office with the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND VICE CHAIRMAN

The Board is pleased to announce that Mr. Zhu Yiwen ("Mr. Zhu") has been appointed as a non-executive Director and vice chairman of the Company with effect from March 30, 2021.

Mr. Zhu, aged 57, is an experienced physician with over 30 years of clinical experience. In September 1987, he started his career at The Affiliated Hospital of Xuzhou Medical University (ࢱψᔼ߅ɽኪڝ᙮ᔼ৫), where he was trained to become a neurosurgeon and served as the director of the Gamma Knife Treatment Center (Тီɠʕː) and the deputy director of the Neurosurgical Department (ग़຾̮߅) and Medical Affairs Department (ᔼ ਕ߅) from November 1998 to October 2004. He subsequently served as the director of the Tumor Radiotherapy Center (໕ᆯ׳ᐕʕː) and the deputy director of the Army-wide Chest Tumor Center (Όࠏ঍௅໕ᆯʕː) of The 455th Hospital of Chinese People's Liberation Army (ʕ਷ɛ͏༆׳ࠏୋ̬ʞʞᔼ৫) from October 2004 to December 2015. Mr. Zhu founded the Group in November 2009 and served as the general manager and a director of the Group until December 2019 and January 2020, respectively. Mr. Zhu studied in clinical medicine at Xuzhou Medical University (ࢱψᔼ߅ɽኪ, formerly known as Xuzhou Medical College (ࢱψᔼኪ৫)) and graduated in July 1987 with a bachelor's degree in medicine. He majored in neurosurgery and obtained his master's degree in clinical medicine from Nanjing Medical University (یԯᔼ߅ɽኪ, formerly known as Nanjing Medical College (یԯᔼኪ ৫)) in July 1992. In August 1999, Mr. Zhu was accredited as an associate-chief physician (ਓ ˴΂ᔼࢪ) and an associate professor by the Personnel Department of Jiangsu Province (Ϫ ᘽ޲ɛԫᝂ). He became a member of Chinese Medical Association (ʕശᔼኪึ) in April 2002 and the 9th Radiation Oncology Specialty Society (׳࢛໕ᆯطᐕਖ਼߅ኪึ) of Jiangsu Branch of the Chinese Medical Association (ʕശᔼኪึϪᘽʱึ) in July 2002.

Pursuant to the appointment letter entered into between the Company and Mr. Zhu, his initial term of office is three years commencing from March 30, 2021 or until the third annual general meeting of the Company since the date of his appointment, whichever is sooner, and unless terminated by not less than one month's prior notice in writing served by either party to the other. Mr. Zhu will hold office until the next general meeting of the Company and is eligible for re-election at such meeting, and he will be subject to retirement by rotation and re-election in accordance with the amended and restated memorandum and articles of association of the Company. According to the terms of Mr. Zhu's appointment letter, he will receive a director's fees of RMB60,000 per annum, as recommended by the remuneration committee of the Board and determined by the Board with reference to his role and responsibilities with the Company.

As of the date of this announcement, Mr. Zhu is one of the controlling shareholders of the Company, and is deemed to be interested in, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), (i) 111,668,436 ordinary shares of the Company held by Century River Holdings Limited, a company wholly-owned by Century River Investment Holdings Limited, which is in turn wholly-owned by Mr. Zhu, (ii) 82,774,691 and 82,774,691 ordinary shares of the Company held by Amber Tree Holdings Limited and Red Palm Holdings Limited, respectively, which are wholly-owned by Red Palm Investment Holdings Limited and in turn wholly-owned by Ms. Zhu Jianqiao ("Ms. Zhu"), one of the controlling shareholders of the Company, daughter of Mr. Zhu and acting in concert with Mr. Zhu pursuant to the concert party confirmation entered into between Mr. Zhu and Ms. Zhu on September 25, 2019, and (iii) 2,400,000 ordinary shares of the Company held by Spruce Wood Investment Holdings Limited, a company wholly-owned by Mr. Ren Ai ("Mr. Ren"), an executive Director, spouse of Ms. Zhu and son-in-law of Mr. Zhu, and 642,597 ordinary shares of the Company through Group & Ray I Limited, Group & Ray II Limited and Group & Ray III Limited, which were awarded to Mr. Ren pursuant to the pre-IPO restricted share scheme adopted by the Company on July 17, 2019.

Saved as disclosed above and as of the date of this announcement, Mr. Zhu has confirmed that (i) he did not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, (ii) he did not have any other relationship with any Director, senior management or substantial shareholders or controlling shareholders of the Company, and (iii) there is no other information that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to Mr. Zhu's appointment.

The Board would like to express its warmest welcome to Mr. Zhu on his appointment.

By order of the Board

Hygeia Healthcare Holdings Co., Limited

Mr. Fang Min

Chairman

Hong Kong, March 30, 2021

As of the date of this announcement, the Board comprises Mr. Fang Min as chairman and non-executive Director, Mr. Zhu Yiwen as vice chairman and non-executive Director, Ms. Cheng Huanhuan, Mr. Ren Ai, Mr. Zhang Wenshan and Ms. Jiang Hui as executive Directors, and Mr. Liu Yanqun, Mr. Chen Penghui and Mr. Ye Changqing as independent non-executive Directors.